Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

Abstract Ibrutinib inhibits Bruton tyrosine kinase while venetoclax is a specific inhibitor of the anti-apoptotic protein BCL2. Both drugs are highly effective as monotherapy against chronic lymphocytic leukemia (CLL), and clinical trials using the combination therapy have produced remarkable result...

Full description

Bibliographic Details

Published in:	Blood Cancer Journal
Main Authors:	Pin Lu, Shengchun Wang, Carrie A. Franzen, Girish Venkataraman, Rebecca McClure, Lei Li, Wenjun Wu, Nifang Niu, Madina Sukhanova, Jianming Pei, Donald A. Baldwin, Reza Nejati, Mariusz A. Wasik, Nadia Khan, Yifan Tu, Juehua Gao, Yihua Chen, Shuo Ma, Richard A. Larson, Y. Lynn Wang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-02-01
Online Access:	https://doi.org/10.1038/s41408-021-00429-z